Fátima Cardoso

Fátima Cardoso's AcademicInfluence.com Rankings

Fátima Cardoso

Medical

#2174

World Rank

#2578

Historical Rank

Oncology

#120

World Rank

#124

Historical Rank

medical Degrees

Fátima Cardoso

Philosophy

#6334

World Rank

#9358

Historical Rank

Logic

#3513

World Rank

#4688

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Fátima Cardoso's Degrees

Doctorate Medicine University of Lisbon
PhD Oncology University of Lisbon

Why Is Fátima Cardoso Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Fátima Cardoso's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. (2006) (1930)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (1411)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. (2006) (1199)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. (2016) (1176)
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007) (983)
Pembrolizumab for Early Triple-Negative Breast Cancer. (2020) (929)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (917)
Breast cancer (2019) (849)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (832)
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018) (820)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study (2011) (758)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) (661)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients (2007) (647)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† (2014) (566)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) (529)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. (2005) (476)
Clinical application of the 70-gene profile: the MINDACT trial. (2008) (468)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (445)
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. (2009) (426)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2017) (405)
Multidisciplinary meeting on male breast cancer: summary and research recommendations. (2010) (386)
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). (2017) (373)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? (2010) (349)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. (2002) (334)
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? (2005) (315)
1st International consensus guidelines for advanced breast cancer (ABC 1). (2012) (308)
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study (2009) (307)
Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. (2016) (289)
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. (2013) (268)
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. (2012) (265)
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial (2006) (253)
Breast cancer in pregnancy: recommendations of an international consensus meeting. (2010) (236)
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy (2009) (226)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (215)
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). (2017) (210)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (2016) (208)
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program (2017) (207)
ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer ( ABC 2 ) (2014) (201)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Facts and controversies in systemic treatment of metastatic breast cancer. (2004) (196)
Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic (2020) (189)
Second international consensus guidelines for breast cancer in young women (BCY2). (2014) (179)
HER2-Low Breast Cancer: Pathological and Clinical Landscape. (2020) (175)
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
Multifactorial approach to predicting resistance to anthracyclines. (2011) (170)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. (2022) (164)
Comparison of prognostic gene expression signatures for breast cancer (2008) (164)
Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). (2018) (163)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. (2011) (161)
Global cancer control: responding to the growing burden, rising costs and inequalities in access (2018) (159)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. (2008) (150)
ESO-ESMO 4rd International Consensus Guidelines for Breast Cancer in Young Women (BCY4). (2020) (149)
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? (2002) (149)
Male breast cancer: a disease distinct from female breast cancer (2018) (146)
Individualization of therapy using Mammaprint: from development to the MINDACT Trial. (2007) (145)
The MINDACT trial: The first prospective clinical validation of a genomic tool (2007) (143)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer (2021) (140)
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review (2015) (138)
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer (2010) (136)
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. (2015) (135)
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer (2020) (134)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (130)
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (129)
First international consensus guidelines for breast cancer in young women (BCY1). (2014) (124)
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice (2005) (116)
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. (2003) (116)
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. (2011) (114)
Central venous access in oncology: ESMO Clinical Practice Guidelines. (2015) (110)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (105)
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. (2021) (101)
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. (2004) (100)
Enhancing global access to cancer medicines (2020) (100)
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. (2007) (99)
Current and future burden of breast cancer: Global statistics for 2020 and 2040 (2022) (92)
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? (2015) (91)
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up†. (2020) (91)
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC (2021) (90)
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. (2001) (90)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2016) (88)
Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. (2017) (88)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) (2010) (85)
International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. (2013) (84)
Management of Male Breast Cancer: ASCO Guideline. (2020) (84)
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. (2004) (84)
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2019) (83)
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. (2002) (78)
Stemming Resistance to HER-2 Targeted Therapy (2009) (77)
Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative. (2011) (76)
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature (2009) (75)
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. (2010) (75)
Recommendations for collection and handling of specimens from group breast cancer clinical trials. (2008) (75)
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper (2014) (75)
Management of locally advanced breast cancer—perspectives and future directions (2015) (75)
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. (2017) (73)
Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing (2002) (73)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). (2014) (73)
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner (2006) (72)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (72)
The requirements of a specialist breast centre (2020) (72)
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. (2009) (71)
HER-2/neu Gene and protein in breast cancer (2004) (71)
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). (2019) (71)
Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. (2016) (68)
Resistance to trastuzumab: a necessary evil or a temporary challenge? (2002) (68)
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. (2018) (67)
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. (2006) (66)
Time for more optimism in metastatic breast cancer? (2014) (65)
Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. (2013) (64)
A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. (2009) (63)
Breast Cancer Under Age 40: a Different Approach (2015) (63)
Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel (2008) (62)
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial (2011) (59)
Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools (2007) (59)
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. (2007) (59)
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. (2015) (58)
Squamous cell carcinoma of the breast. (2000) (58)
What clinicians need to know about antioestrogen resistance in breast cancer therapy. (2006) (57)
Mammographic screening detects low-risk tumor biology breast cancers (2014) (57)
Research needs in breast cancer (2016) (57)
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial (2017) (56)
An update on male breast cancer and future directions for research and treatment. (2013) (55)
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. (2014) (55)
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. (2013) (55)
European Breast Cancer Conference manifesto on breast centres/units. (2017) (54)
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. (2003) (54)
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. (2004) (53)
BRCA in breast cancer: ESMO Clinical Practice Guidelines. (2011) (51)
Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. (2004) (51)
Management of locally advanced breast cancer—perspectives and future directions (2015) (48)
Molecular targeted therapies in breast cancer: where are we now? (2007) (48)
Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. (2009) (48)
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). (2007) (48)
Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes. (2013) (47)
Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. (2016) (46)
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study (2008) (45)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2011) (45)
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. (2014) (43)
Molecular profiling of head and neck tumors (2004) (42)
Targeting the ubiquitin-proteasome pathway in breast cancer. (2004) (42)
Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization. (2016) (42)
Bringing molecular prognosis and prediction to the clinic. (2005) (41)
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: A Clinical Trial (2018) (41)
European perspective for effective cancer drug development (2014) (40)
MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. (2020) (40)
Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. (2007) (40)
Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology (2019) (40)
Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (2016) (40)
Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer (2019) (37)
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). (2015) (35)
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. (2020) (35)
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. (2005) (34)
Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites (2003) (34)
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. (2008) (34)
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. (2012) (33)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. (2015) (32)
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? (2011) (32)
A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer (2013) (31)
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program (2017) (30)
Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis (2020) (30)
Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy (2020) (29)
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma. (2001) (28)
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. (2021) (28)
Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. (2004) (28)
Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status (2016) (27)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. (2020) (27)
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer (2016) (26)
Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. (2019) (26)
Use and abuse of taxanes in the management of metastatic breast cancer. (2003) (25)
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial (2021) (25)
Metastatic breast cancer patients: the forgotten heroes! (2009) (24)
Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program (2015) (24)
Review on the clinical use of eribulin mesylate for the treatment of breast cancer (2016) (23)
A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer. (2018) (23)
Targeting CDK4/6 pathways and beyond in breast cancer. (2019) (23)
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. (2012) (22)
Facts and controversies in the use of trastuzumab in the adjuvant setting (2008) (22)
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. (2013) (22)
Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab (2008) (21)
Current perspectives of epothilones in breast cancer. (2008) (21)
Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. (2009) (20)
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer (2012) (20)
New data on chemotherapy in the adjuvant setting. (2003) (20)
Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. (2001) (20)
Molecular forecasting of breast cancer: time to move forward with clinical testing. (2006) (20)
Microarray technology and its effect on breast cancer (re)classification and prediction of outcome (2003) (19)
Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. (2017) (18)
Use of trastuzumab for the treatment of early stage breast cancer (2006) (18)
The pipeline of new anticancer agents for breast cancer treatment in 2003. (2003) (18)
Remaining controversies in the upfront management of advanced ovarian cancer (2004) (18)
Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. (2009) (18)
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. (2014) (18)
Abstract P5-13-01: Patterns of Breast Cancer Relapse According to Breast Cancer Subtypes in Lymph Node-Negative Breast Cancer — Results from International Breast Cancer Study Group Trials VIII and IX (2010) (17)
Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey. (2018) (17)
First-Line Treatment of Metastatic Breast Cancer (2006) (17)
The best use of chemotherapy in the adjuvant setting. (2003) (17)
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. (2012) (16)
Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference (2019) (16)
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies (2011) (16)
PARP inhibitors coming of age (2020) (16)
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002 (2002) (16)
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. (2020) (15)
Progress in systemic therapy for breast cancer: an overview and perspectives (2003) (15)
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy (2021) (15)
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. (2022) (15)
HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. (2002) (15)
MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. (2009) (14)
Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice (2016) (14)
BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC) (2016) (14)
Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220. (2020) (14)
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. (2017) (14)
Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2008) (14)
An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®). (2017) (13)
Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto (2021) (13)
Extended adjuvant endocrine therapy - A standard to all or some? (2017) (13)
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer. (2013) (13)
Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation (2008) (13)
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. (2004) (13)
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. (2020) (13)
Breast cancer surgery with augmented reality (2021) (13)
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients (2017) (13)
Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial (2020) (13)
Challenges in breast cancer clinical trial design in the postgenomic era (2004) (13)
A Phase I Dose Escalation Study of Steroid Sulfatase Inhibitor BN83495/STX64 in Postmenopausal Women with ER Positive Breast Cancer. (2009) (13)
Breast cancer gene expression profiling: clinical trial and practice implications. (2005) (12)
Optimizing Anthracycline Therapy for Node Positive Breast Cancer (2002) (12)
Recent advances in adjuvant systemic therapy for early-stage breast cancer. (2008) (12)
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
Chemoprevention for breast cancer. (2012) (12)
Are we HER-ting for innovation in neoadjuvant breast cancer trial design? (2009) (12)
Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden? (2016) (12)
Small breast cancers: when and how to treat. (2014) (12)
Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial. (2021) (11)
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). (2014) (10)
The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective (2021) (10)
European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission. (2022) (10)
Better translation from bench to bedside: Breakthroughs in the individualized treatment of cancer (2009) (10)
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. (2021) (10)
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. (2020) (10)
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial (2022) (10)
Challenges in optimizing care in advanced breast cancer patients: Results of an international survey linked to the ABC1 consensus conference. (2015) (10)
Oncology research in late twentieth century and turn of the century Portugal: a scientometric approach to its institutional and semantic dimensions (2017) (10)
Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study. (2017) (9)
0073 The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer (2009) (9)
Breast cancer and molecular medicine (2006) (9)
Cognitive, emotional, and behavioral mediators of the impact of coping self‐efficacy on adaptation to breast cancer: An international prospective study (2021) (9)
The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions (2012) (8)
3D digital breast cancer models with multimodal fusion algorithms (2020) (8)
Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). (2011) (8)
Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). (2010) (8)
[The new generation of breast cancer clinical trials: the right drug for the right target]. (2008) (8)
Abstract GS4-05: Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X (2020) (8)
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment (2013) (8)
Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC) (2010) (8)
Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers. (2012) (8)
Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis (2022) (7)
Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back? (2018) (7)
Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer patients (2003) (7)
Better characterisation of estrogen receptor (ER) positive luminal subtypes using genomic grade (2005) (7)
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial (2020) (7)
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. (2020) (7)
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. (2019) (7)
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer (2020) (7)
SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC). (2016) (7)
TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer (2006) (7)
Combined use of genomic prognostic and treatment response predictors in breast cancer (2008) (7)
Tamoxifen therapy for patients with breast cancer (2013) (7)
Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses (2022) (7)
Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. (2004) (7)
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. (2002) (7)
5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab (2009) (7)
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. (2002) (7)
Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice? (2003) (6)
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study. (2002) (6)
Show me the genes – I will tell you who/how to treat! (2005) (6)
Automatic detection of perforators for microsurgical reconstruction (2020) (6)
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. (2009) (6)
444 The EORTC 10041/BIG 03–04 MINDACT trial is feasible: first results of the pilot phase (2010) (6)
Abstract OT3-02-02: ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer (2017) (6)
Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of "grade 2" tumors. (2005) (6)
150O_PRNot all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy (2017) (6)
Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe (2020) (6)
Editorial: Why are guidelines not followed in clinical practice? (2017) (6)
Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial (2022) (6)
Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. (2021) (5)
Breast cancer in 2014: A call back to reality! (2015) (5)
Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial) (2016) (5)
Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer (2021) (5)
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. (2014) (5)
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) (2022) (5)
Protocol for the Implementation and Assessment of “MoodUP”: A Stepped Care Model Assisted by a Digital Platform to Accelerate Access to Mental Health Care for Cancer Patients Amid the COVID-19 Pandemic (2021) (5)
A rude awakening from tumour cells. (2018) (5)
A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. (2012) (5)
Evaluation of Microtubule Associated Parameters (MTAPs) as predictive markers for Advanced Breast Cancer (ABC) patients treated with docetaxel (2001) (5)
Better characterization of estrogen receptor (ER) positive luminal subtypes of breast cancer using genomic grade. (2005) (5)
OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy. (2006) (5)
Everolimus (Afinitor®), Trastuzumab (H), and Paclitaxel (P) or Vinorelbine (V) in the Treatment of HER-2+ Metastatic Breast Cancer (MBC) Patients (Pts) Pre-Treated with Lapatinib-Containing Therapy: Pooled Analysis of 2 Phase I Studies. (2009) (5)
Non-endocrine systemic therapies in advanced breast cancer (2003) (5)
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies (2020) (4)
Controversies in adjuvant systemic therapy of breast cancer. Part I: areas of controversy in the adjuvant systemic therapy of endocrine non-responsive breast cancer (2002) (4)
1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (2020) (4)
The EUSOMA recommendations for the management of young women with breast cancer (2012) (4)
Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis (2019) (4)
Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. (2017) (4)
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients (2013) (4)
Quality-of-life methodology in hormone receptor–positive advanced breast cancer: current tools and perspectives for the future (2021) (4)
Gaps in Care and Support for Patients With Advanced Breast Cancer: A Report From the Advanced Breast Cancer Global Alliance (2021) (4)
The ESMO guideline strategy: an identity statement and reflections on improvement. (2015) (4)
The Porto European Cancer Research Summit 2021 (2021) (4)
An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+ Advanced Breast Cancer (ABC). (2009) (4)
The role of capecitabine in the management of breast cancer in elderly patients (2011) (4)
Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials. (2013) (4)
Neoadjuvant hormonal therapy in locally advanced breast cancer (1998) (4)
The mutual determination of self-efficacy to cope with cancer and cancer-related coping over time: a prospective study in women with breast cancer. (2022) (4)
Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials. (2009) (4)
Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review. (2018) (4)
Pharmacokinetics and tolerability of lapatinib administered once daily in combination with tamoxifen. (2009) (4)
Prevalence of silent breast cancer in autopsy specimens, as studied by the disease being held by image-guided biopsies: The pilot study and literature review (2017) (4)
The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual (2011) (4)
Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: Analysis of risk factors including the 70-gene signature (2018) (3)
Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results (2005) (3)
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry (2020) (3)
Progression-free survival and quality of life in metastatic breast cancer: The patient perspective (2022) (3)
Reply to the letter to the editor 'Insertion of central venous catheters (CVCs): any changes in the past ten years' by Biffi et al. (2016) (3)
Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe! (2017) (3)
5075 Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer (2009) (3)
Neoadjuvant endocrine therapy: for whom, for how long? (2012) (3)
Targeted Axillary Dissection after Chemotherapy: Feasibility Study with Clip and Carbon Dye Tattoo – Neotarget Trial (2021) (3)
A rude awakening from tumour cells (2018) (3)
p-53 gene mutations as a predictive marker in advanced breast cancer patients randomly treated either with doxorubicin or with docetaxel (2004) (3)
The voice of youth. (2006) (3)
New tools for assessing breast cancer recurrence. (2008) (3)
Anthracyclines in the treatment of early breast cancer friend or foe? (2022) (3)
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2022) (3)
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45. (2018) (3)
Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer. (2009) (3)
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC). (2020) (3)
Digital analysis of distant and cancer-associated mammary adipocytes (2020) (3)
Editorial: Overdoing in breast cancer: The risks of over-screening, over-diagnosing and over-treating the disease. (2017) (3)
A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2* (2006) (3)
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer. (2002) (3)
Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer (2001) (3)
Abstract P4-11-08: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial (2012) (3)
A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments☆ (2020) (3)
Abstract OT1-02-07: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer (2017) (3)
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. (2022) (3)
E1. Tailored systemic treatment for breast cancer: dream or reality? (2004) (3)
Gene expression module associated with Insulin-like Growth Factor 1 (IGF1) pathway activation predicts poor response to tamoxifen in women with ER+/HER2- early breast cancer (BC) (2009) (2)
Predicting the efficacy of anthracyclines in breast cancer (BC): The results of the TOP trial and their validation in the BIG 00-01 trial. (2009) (2)
Predicting Effective Adaptation to Breast Cancer to Help Women BOUNCE Back: Protocol for a Multicenter Clinical Pilot Study (2022) (2)
Breast Cancer in Young Women – a Clinical Challenge to Be Addressed in a Multidisciplinary Setting (2012) (2)
Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back: study protocol for a multicenter clinical pilot (Preprint) (2021) (2)
93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) (2021) (2)
Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen (2005) (2)
Highlights in breast cancer from ASCO 2016 (2016) (2)
A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. (2009) (2)
From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. (2017) (2)
Abstract P1-07-08: Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial (2018) (2)
The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge (2022) (2)
Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. (2012) (2)
The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge (2022) (2)
Abstract P5-23-01: Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry (2018) (2)
Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself. (2006) (2)
[Towards an individualization of systemic treatment of breast tumors]. (2006) (2)
Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial (2017) (2)
Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC) (2021) (2)
Abstract GS4-11: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status (2021) (2)
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer (2021) (2)
92OEverolimus (EVE) + letrozole (LET) in Asian patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Results of a subgroup analysis from the BOLERO-4 study (2017) (2)
Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer) (2021) (2)
Abstract P2-03-01: Are all small tumors low risk? Characterization of small invasive node negative breast cancers (BC) enrolled in the EORTC 10041/BIG 3-04 (MINDACT) trial (2015) (2)
The Interplay Between Trait Resilience and Coping Self-efficacy in Patients with Breast Cancer: An International Study (2022) (1)
Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen (2005) (1)
P1-07-06: High Concordance of Protein (by IHC), Gene (by FISH; HER-2 Only) and Microarray Readout (by TargetPrint) of ER/PR/HER2: Results from the MINDACT Trial. (2011) (1)
Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13) (2023) (1)
Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer (2019) (1)
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. (2022) (1)
Personalized Medicine by the Use of Microarray Gene Expression Profiling (2020) (1)
3D Breast Volume Estimation (2021) (1)
Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®)" [Eur J Cancer 75 (April 2017) 5-13]. (2018) (1)
Abstract P5-23-02: Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program (2018) (1)
412 The EORTC 10041/BIG 03-04 MINDACT Trial Quality Assurance Program – Results of the Questionnaire for Pathologists (2012) (1)
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer (2022) (1)
OR26 THE CHALLENGES IN OPTIMISING CARE IN PATIENTS WITH ADVANCED BREAST CANCER: RESULTS OF AN INTERNATIONAL SURVEY (2013) (1)
The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”? (2018) (1)
The 70-Gene Profile (MammaPrintTM) Is an Independent Predictor of Breast Cancer Specific Survival for Women 65 Years of Age or Older. (2009) (1)
Mammographic Screening: Good Prognosis Tumor Biology in Screen-detected Breast Cancers (2012) (1)
Molecular classification of breast carcinomas by immunohistochemistry (IHC) using the tissue microarrays (TMA): new subtypes with clinical relevance? (2004) (1)
1835 Health-related quality of life in advanced breast cancer: A systematic review on reporting of methodological and clinical issues in randomized controlled trials (2015) (1)
Abstract P2-11-08: Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial (2017) (1)
Predictive Molecular Markers: A New Window of Opportunity in the Adjuvant Setting (2003) (1)
0072 The 70-gene MammaPrint signature for optimal risk stratification in endocrine responsive breast cancer (2009) (1)
Capecitabine as adjuvant therapy for elderly breast cancer (BC) patients (pts): a pilot study (2006) (1)
213 Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group (2010) (1)
Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy (2020) (1)
Supporting Resource-Stratified Metastatic Breast Cancer Policy Development: A Global Policy Analysis (2018) (1)
Expert Discussion: Highlights from ABC6: Bridging the Gap and Insights in This First Virtual ABC Conference and from 10 Years ABC Consensus (2021) (1)
Oxaliplatin and 5-fluorouracil in heavily pretreated patients with ovarian carcinoma: A well tolerated and efficient treatment (2007) (1)
International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients (2023) (1)
Sunitinib in breast cancer: friend or foe. (2009) (1)
5006 ORAL Eribulin Mesylate EMBRACE Study – Survival Analysis Excluding Patients Re-challenged With Therapies of the Same Class (2011) (1)
Breast cancer screening: Biology of tumors detected by analog and digital mammography. (2013) (1)
FROM EARLY TO METASTATIC BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF DISTANT RECURRENCE RATES (2021) (1)
Putting words into practice (2019) (1)
Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. (2010) (1)
E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting (2012) (1)
Management of Advanced Breast Cancer in Young Women: What’s New in Systemic Treatment (2020) (1)
Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer. (2003) (1)
Topoisomerase-II as a predictive marker for response to anthracyclines (2007) (1)
1759P Cancer care during COVID-19: Data from 157 patient organisations (2020) (1)
Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden? (2016) (1)
Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients. (2019) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer (2018) (1)
Abstract PS6-01: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status (2021) (1)
1604P Global survey of 104 cancer patient organisations reveals devastating impact of COVID-19 (2021) (1)
Abstract PD6-11: PD6-11 Evaluation of the Sensitivity to Endocrine Therapy Index (SET2,3) in Early Male Breast Cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program (2023) (0)
Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer (2021) (0)
Understanding the current use of breast cancer multigene signatures in clinical practice across Europe: global results from the PROCURE Project (2022) (0)
How the recent data from metastatic trials inform us on treatment opportunities for patients with early breast cancer? (2019) (0)
Prevalence of Imaging-Detected Silent Female Breast Cancer in Autopsy Specimens: A Study Using Image-Guided Biopsies (2022) (0)
State-of-the-art management of HER-2+ disease (2011) (0)
91O_PRAnalysis of the gaps on metastatic breast cancer policies and advocacy efforts to support policy development across the patient journey in Asia (2017) (0)
Aid of a machine learning algorithm can improve clinician predictions of patient quality of life during breast cancer treatments (2023) (0)
Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer (ABC) in Asia and Middle East (ME): Results from the Count Us, Know Us, Join Us (CUKUJU) survey (2020) (0)
Metastatic Breast Cancer Session (2008) (0)
Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens (2004) (0)
Prospective, Multi-Center, Artificial Intelligence Study for Early Prediction of Serious Events under Treatment Is Now Open for Recruitment in Breast Cancer - OMCAT Trial in Progress (2022) (0)
Abstract PD3-09: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study (2018) (0)
Shared decision-making in breast cancer care: Evidence from a scoping literature review and a survey across breast units in Europe (2022) (0)
Abstract OT-14-01: Adaption of the EORTC quality of life breast cancer module for male breast cancer - phase I (2021) (0)
Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study (2022) (0)
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care. (2023) (0)
Abstract PS11-01: Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial (2021) (0)
Adjuvant Treatment of HER-2 positive Breast Cancer: Overview of Trastuzumab and Lapatinib (2007) (0)
Potential importance of PKC-alpha activity in defining breast tumor luminal/basal phenotype (2003) (0)
Abstract P2-13-22: Comparative effectiveness of initiating chemotherapy with or without trastuzumab based regimens as third line treatment for metastatic breast cancer (2022) (0)
70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT (2020) (0)
[News in the medical treatment of breast cancer]. (2003) (0)
E8. Breast cancer: Whom to treat and how to treat? (2010) (0)
2PAgreement in risk assessment among breast cancer specialists: A survey within the MINDACT cohort (2015) (0)
Associations between Physical Exercise, Quality of Life, Psychological Symptoms and Treatment Side Effects in Early Breast Cancer (2022) (0)
Speaker's abstract Session 1. News since St. Gallen 2001New data on chemotherapy in the adjuvant setting (2003) (0)
Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288. (2020) (0)
BENEFIT ASSESSMENT OF NEW METASTATIC BREAST CANCER (MBC) TREATMENTS – A MULTI-STAKEHOLDER APPROACH (2019) (0)
GLOBAL SURVEY OF 104 CANCER PATIENT ORGANISATIONS REVEALS DEVASTATING IMPACT OF COVID-19 (2021) (0)
Reply to letter from Suguatti et al. (2017) (0)
Reply to 'Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease' by U. Gueth et al. (2013) (0)
132P The psychological impact of the COVID-19 pandemic on patients with early breast cancer (2021) (0)
HSR22-156: Patient Perspectives on Progression-Free Survival and Quality of Life in Metastatic Breast Cancer (2022) (0)
Vision and collaboration: essential ingredients for the future of breast cancer research. Editorial overview (2004) (0)
Bringing Safe and Effective Therapies to Premenopausal Women with Breast Cancer: Efforts to Broaden Eligibility Criteria. (2021) (0)
PATIENTS HELPING PATIENTS: DEVELOPMENT AND EVALUATION OF A VIRTUAL PEER NAVIGATION PROGRAM FOR METASTATIC/ADVANCED BREAST CANCER (2021) (0)
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management (2023) (0)
4LBA RNA, protein or gene? ER, PgR and HER2 by local and central pathology review, and microarray readout (by TargetPrint) in the EORTC 10041/BIG 03-04 MINDACT trial (2014) (0)
Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers (2020) (0)
Reply to 'Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease' by U. Gueth et al. (2013) (0)
E9. Managing metastatic breast cancer: the European School of Oncology – Metastatic Breast Cancer Task Force session (2010) (0)
Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer (2020) (0)
Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study (2022) (0)
Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer (2022) (0)
Abstract PS9-11: Health-related quality of life for margetuximab + chemotherapy vs. trastuzumab + chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+ metastatic breast cancer (2021) (0)
[Regional Cancer Registry and clinical research in Portugal: challenges and opportunities]. (2014) (0)
Supporting Breast Cancer Early Detection and Diagnosis: A Global Metastatic Breast Cancer Policy Analysis and Promising Practice From Brazil (2018) (0)
OP-ANNO180192 1634..1657 (2018) (0)
Adjuvant Chemotherapy of Breast Cancer (2009) (0)
Cancer care during COVID-19: Data from 157 patient organizations. (2021) (0)
PO-208 Human zebrafish xenografts as therapy sensors for breast cancer (2018) (0)
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer (2021) (0)
HER2 Inhibition and Clinical Achievements (2013) (0)
Abstract PD4-06: PD4-06 Obesity-associated changes in transcriptomic profile and immune landscape of primary breast cancer revealed by bulk and single-cell gene expression data (2023) (0)
DESIGNING A PEER NAVIGATION PROGRAM FOR PATIENTS WITH ADVANCED BREAST CANCER (2019) (0)
Management of breast cancer in men (2021) (0)
Quality Criteria for Multidisciplinary Oncology Guidelines - the ECCO Multidisciplinary Clinical Guidelines Forum (2013) (0)
Dual HER-2/EGFR tyrosine kinase inhibitors (2001) (0)
Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project (2022) (0)
O Registo Oncológico Regional Sul e a Investigação Clinica em Portugal: Desafios e Oportunidades Regional Cancer Registry and Clinical Research in Portugal: Challenges and Opportunities (2014) (0)
Phase III trial of chemotherapy ? HerceptinR in metastatic breast cancer (2001) (0)
Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer. (2023) (0)
ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology. (2023) (0)
Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial (2021) (0)
336TiP Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial (2021) (0)
Abstract P4-12-03: Assessment of quality of life (QoL) in patients with metastatic breast cancer (MBC) in clinical practice: A real-world multi-country survey (2022) (0)
The dosing, schedule and route of chemotherapy in gynaecological cancers (2004) (0)
Correction: Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study (2023) (0)
Duration of adjuvant tamoxifen treatment (2001) (0)
187P Development of a patient-centered core outcome set for metastatic breast cancer (2022) (0)
Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45 (Annals of Oncology (2020) 31(2) (283–288), (S0923753419360843), (10.1016/j.annonc.2019.10.027)) (2020) (0)
# 3016 - Definition of Clinically Distinct Subtypes Within Estrogen Receptor Positive Luminal Breast Carcinomas (2005) (0)
TRANSBIG: The way forward in breast cancer research (2005) (0)
Changes over time in self-efficacy to cope with cancer and well-being in women with breast cancer: a cross-cultural study. (2023) (0)
The future of systemic treatment of breast cancer (2004) (0)
Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Breast Group. (2013) (0)
The 70-gene profile is a powerful predictor of disease outcome in breast cancer patients with 1–3 positive lymph nodes (2008) (0)
EUSOMA/ABC Global Alliance quality indicators for metastatic breast cancer care (2023) (0)
PO56 BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTOR–POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HER2 (2015) (0)
Analysis of the Gaps on Metastatic Breast Cancer Global Policies and Advocacy Efforts to Support Policy Development across the Patient Journey (2017) (0)
Prevalence of Imaging Detected Silent Male Breast Cancer in Autopsy Specimens: Study of the Disease Held by Image-Guided Biopsies (2023) (0)
GW5638: a new antiestrogen (2001) (0)
Sequential tumour biopsies in phase I trials (2002) (0)
Abstract OT2-15-01: Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs (2022) (0)
New strategies for the precision treatment of HER2-driven tumours (2019) (0)
Abstract P5-14-01: Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial (2023) (0)
Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer (2023) (0)
Augmented Reality in Breast Surgery Education (2023) (0)
Silent breast cancer: study of the disease prevalence held by image-guided biopsies on autopsy specimens: the pilot study (2017) (0)
Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer (2019) (0)
Abstract P3-12-10: Is the Biology of Breast Cancer (BC) Changing through Time? Results of a Two-Decade Single Belgium Institution Study (2010) (0)
ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy. (2012) (0)
ESMO Guidelines Committee. (2018) (0)
Prevalence of silent breast cancer in autopsy specimens, as studied by the disease being held by image‑guided biopsies: The pilot study (2017) (0)
E12. Progress in systemic therapy for breast cancer (2002) (0)
ASCO 2009: What’s New in Breast Cancer Therapy? (2009) (0)
Metastatic Breast Cancer (2016) (0)
The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer (2022) (0)
Her-2/neu and topoisomerase IIaexpression in primary and metastatic breast cancer (2001) (0)
This is a repository copy of Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. (2018) (0)
Regularization Techniques in Radiomics: A Case Study on the Prediction of pCR in Breast Tumours and the Axilla (2019) (0)
Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early-stage breast cancer: Findings from the Breast International Group (BIG) 1-98 trial. (2012) (0)
PO58 EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS PLUS LETROZOLE IN ER+ HER2− METASTATIC BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-4 (2013) (0)
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review (2015) (0)
Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04 (2018) (0)
Oncologist and patient roles in assessing current and future treatment for metastatic breast cancer: Results of an observational linguistic study (2008) (0)
State of the art of the management of metastatic breast cancer (MBC) (2002) (0)
The need for post-mastectomy radiotherapy in patients with IBC (2015) (0)
Establishing anchor-based minimally important differences (MID) for the EORTC QLQ-C30 scales across multiple cancer sites (2019) (0)
Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial (2017) (0)
Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 (2018) (0)
Evaluation of HER-2 protein expression in primary breast cancer (PBC) by immunohistochemistry (IHC): An interlaboratory study assessing the reproducibility of HER-2 testing (2001) (0)
Evidence-based approach to determine meaningful change in scores of the EORTC QLQ-C30 in breast and head and neck cancer : on behalf of the EORTC Breast, Head and Neck and Quality of Life Groups (2018) (0)
Adjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors (2008) (0)
The triple negative profile dilemma and its clinical outcome in early breast cancer (2006) (0)
Consensus on the utility of breast cancer multigene signatures in routine clinical practice: Results of the PROCURE Project. (2022) (0)
Iressa inhibits growth of HER-2-overexpressing cells (2001) (0)
Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study (2023) (0)
Contents Vol. 8, 2013 (2013) (0)
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial (2020) (0)
The Changing Clinical Research Pathway (2019) (0)
A Global Perspective on Cooperation (2019) (0)
De-escalation of early breast cancer therapy: Umberto Veronesi’s legacy (2021) (0)
Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population: An open-label multicenter randomized phase II selection trial of the EORTC (2013) (0)
Primary chemotherapy with CEF-infu (2002) (0)
Challenges and Threats (2019) (0)
Subject Index Vol. 3, 2008 (2008) (0)
Jointly Improving Women’s Health Worldwide – Current Focus of the ‘International Working Group’ of the German Society of Obstetrics and Gynaecology (AG FIDE) (2009) (0)
Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: a survey within the MINDACT cohort (2022) (0)
ABC 1: 1st International Consensus Guidelines Conference for Advanced Breast Cancer (2013) (0)
THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) (2021) (0)
5084 Pharmacokinetics and tolerability of lapatinib administered once daily in combination with tamoxifen (2009) (0)
Systemic Therapy (2019) (0)
Contents Vol. 3, 2008 (2008) (0)
In Honor of Hans-Jörg Senn (2023) (0)
Optimal duration and effectiveness of neoadjuvant endocrine therapy in breast cancer – Retrospective series (2020) (0)
Abstract PS9-16: Long-term personal, social and financial impact of advanced breast cancer: Results from the invisible woman 2.0, a pan-European patient and carer survey (2021) (0)
Workshop Report ‘Responding to Challenges in Metastatic Breast Cancer - an Academy for Rising Stars in Oncology', 25th-27th January 2013, Lisbon (2013) (0)
Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8–11, 2020 (2021) (0)
E12. Progress in systematic therapy for breast cancer (2002) (0)
Abstract P4-17-02: Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group (2013) (0)
Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. (2022) (0)
The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”? (2018) (0)
Abstract P4-02-02: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer (2022) (0)
Abstract P1-07-02: Withdrawn (2018) (0)
Treatment of Advanced Disease: Guidelines (2017) (0)
Abstract OT3-16-01: Follow-up in early (EBC) and locally advanced (LABC) breast cancer patients; EORTC protocol 1617-QLG-BCG-ROG (2020) (0)
Her-2/neu expression in primary breast cancer and its lymph node metastases (2001) (0)
The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer (2022) (0)
Abstract OT3-11-01: Adaption of the EORTC QLQ-breast cancer module for male BC: Phase I (2020) (0)
The development of an automatic tool to improve perforators detection in Angio CT in DIEAP flap breast reconstruction (2018) (0)
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023) (0)
Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations (2020) (0)
Abstract P1-07-03: Unmet needs and future applications of breast cancer multigene signatures in routine clinical practice: results from the European PROCURE Project (2023) (0)
244PDEverolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 (2017) (0)
P30 The Jules Bordet Onco-Geriatric Pilot Unit: one-year report (2009) (0)
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. (2023) (0)
Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results (2020) (0)
SA 11.3 Can we omit adjuvant endocrine therapy? (2023) (0)
Abstract P1-03-04: Zebrafish xenografts as a fast screening platform for bevacizumab impact on tumor growth, angiogenesis and micrometastasis in breast cancer (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Fátima Cardoso?

Fátima Cardoso is affiliated with the following schools:

National Taiwan University
Brighton and Sussex Medical School
Université libre de Bruxelles
Medical University of Graz
University of Lisbon
University of Porto
University of Oxford
Nagoya City University
University of Modena and Reggio Emilia
Queen's University at Kingston
University of Edinburgh

Fátima Cardoso's Academic­Influence.com Rankings

Fátima Cardoso's Degrees

Why Is Fátima Cardoso Influential?

Fátima Cardoso's Published Works

Published Works

What Schools Are Affiliated With Fátima Cardoso?

Fátima Cardoso's AcademicInfluence.com Rankings